Navigation Links
Clemson chemists present revolutionary teaching concepts
Date:2/15/2009

," said Bhattacharyya, who will evaluate the research project and will assess the effects of the curriculum and how to present it to schools large and small.

The researchers say the majority of chemistry courses are mired in content that has not changed in years and was designed for students who go on to major in chemistry, rather than attempting to reach students who are taking chemistry to help them understand their studies in other areas.

"We would like huge, expensive chemistry books to become obsolete," said Cooper. "Our text will be quite different than those on the market now. It is written in an engaging style that has a logical flow. Students will interact directly with web-based materials that promote skills such as problem-solving and investigations of difficult concepts. All of the materials we develop will be based on our research on effective teaching and learning."


'/>"/>

Contact: Melanie Cooper
cmelani@clemson.edu
864-650-2755
Clemson University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Clemson chemists discover new way antioxidants fight debilitating diseases
2. Clemson scientists shed light on molecules in living cells
3. Clemson physicist addresses international forum on thermoelectric energy
4. NIH recognizes Clemson nanotechnology for molecule tracking
5. Clemson bioengineer wins prestigious Early Career Award
6. NIH awards Clemson bioengineer $1.5 million to improve durability of tissue heart valves
7. National Science Foundation grants Clemson professors award to develop nanoprobes
8. US Senate confirms Clemson University engineering Dean Esin Gulari to National Science Board
9. Clemson researchers advance nano-scale electromechanical sensors
10. Clemson physicist Apparao Rao named Fellow of the American Physical Society
11. Chemists get grip on slippery lipids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2015)... BEDFORD, Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... services, today reported financial results for its second quarter ended ... quarter of 2015 was $4.5 million, a decrease of 33% ...  Net income in the second quarter of 2015 was $0.3 ... million, or $0.04 per diluted share, in the same period ...
(Date:7/21/2015)... 21, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market ... that it has filed provisional patent 62/192218 for ... This invention highlights next generation payment ... account, but also the user using unique personal ...
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... in French . , Prof. Claudio Cuello at ... can emulate Alzheimer,s disease in humans, enabling research that will ... brain condition leading to a progressive decline of memory and ... in the past, rats are more intelligent than other rodents ...
... This release is available in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2010-03/sfeb-ftc032910.php,">Chinese ... known antiepileptic agent widely used throughout the world. ... have suggested that, as for other anticonvulsant drugs ... including valproate and carbamazepine, phenytoin may have mood-stabilizing ...
... Helmholtz Zentrum Mnchen has launched a new cooperative project ... therapeutic approaches against lymphoid tumors. With a two-year grant ... two partners will seek to further develop lentiviral vector ... cancer form and to devise approaches for treatment. ...
Cached Biology News:From the clinics to the bench and back -- phenytoin as a mood stabilizer? 2Development of new anti-cancer gene therapy approach using lentiviral vectors 2
(Date:7/30/2015)... , July 30, 2015 ... by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, ... & Development, Preclinical, Clinical Trial), by End Users - ... Market is expected to reach USD 2,107.99 million by ... CAGR of 15.29%. Browse more than ...
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
(Date:7/29/2015)... Sanofi, a global and ... quarter of 2015. CEO Olivier Brandicourt ... in different businesses. Watch video interview ... Topics covered in the interview include:  ... Performance drivers - Diabetes ...
(Date:7/29/2015)... MONTREAL , July 29, 2015 /PRNewswire/ - BioAmber Inc. ... Laurin , the Company,s Chief Financial Officer has resigned.  ... former Chief Financial Officer who retired in December 2014, ... search for a permanent successor.     Andy ... Mr. Laurin and ensure a smooth transition.  Andy was ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... ... that have $1 - $20 million in yearly revenues and have experienced significant growth over ... , ... September 24, 2009 -- Orange County has become a hub for innovation and growth and ...
... NEW YORK, Sept. 24 Reportlinker.com announces that a new market ... World Market for Cancer Therapeutics and Biotherapeutics, 3rd. ... http://www.reportlinker.com/p0119229/World-Market-for-Cancer-Therapeutics-and-Biotherapeutics-3rd-Edition-The.html , , ... year. This number is expected to increase by 2.4% by 2020 ...
... , , WAYNE, ... Bonatti, M.D., Professor of Surgery and Director of Coronary Surgery ... Center in Baltimore, has completed the world,s first use of ... robotic and fully endoscopic heart surgery. The new cardiopulmonary bypass ...
Cached Biology Technology:Southern California Venture Network to Recognize Local Companies At 2009 Emerging Growth Awards 2Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 2Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 3Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 4Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 5Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 6Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 7Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 8Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 9Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 10Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 11MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 2MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 3MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 4
Without sodium bicarbonate. Sterile, Cell culture tested...
... a fluorescence scanner with 1 or 2 ... Protein, CGH, ) spotted on standard slides ... InnoScan700 scanners include three different models:, ... simultaneous dual fluorescence scanner (635nm and 532nm). ...
... Open Frame DNAscope is an integrated confocal ... and readily integrated into your specific application. ... we can tailor the system to your ... optical scanning design has been modularized and ...
... Hybridization chambers with forced convection Temperature range ... to 99.9 C / 212 F Patented ... results DS controller Timer 0 to ... accuracy of a tenth of a degree ...
Biology Products: